PPT-SOF/VEL

400100 mg qd N 120 N 120 W12 SOF RBV gt 18 years Chronic HCV infection Genotype 2 Naïve or pretreatment with IFNbased regimen Compensated cirrhosis allowed No HBV or HIV coinfection. With Or Without Ribavirin Is Safe and Efficacious in Liver Transplant Recipients With HCV Recurrence: . Interim Results of a European Multicenter Compassionate Use Program. Herzer K,. 1. . Welzel. . HCV WORLD CAB .  FEBRUARY 2014. BANGKOK, THAILAND. When to Treat HCV. . HCV Direct-Acting . Antivirals. (. DAAs. ) in . development. . OVERVIEW. Know your epidemic: what matters. qd. + SOF 400 mg . qd. N = 40. W12. 18-70 years. Chronic HCV infection. Genotype 4. HCV RNA > 10 000 IU/ml. Naïve or pre-treatment. with PEG-IFN + RBV. Compensated cirrhosis allowed. No HBV or HIV co-infection. With Or Without Ribavirin Is Safe and Efficacious in Liver Transplant Recipients With HCV Recurrence: . Interim Results of a European Multicenter Compassionate Use Program. Herzer K,. 1. . Welzel. . N = 69. >. 18 years. Failure to SOF/VEL . or SOF/VEL + VOX . (LEPTON study). Any genotype. Compensated cirrhosis allowed. No HBV or HIV co-infection. Open-label. SOF/VEL: 400/100 mg FDC QD ; RBV: weight based in twice daily dose . N = 12. N = 13. W24. W16. SOF + EBR + GZR + RBV. > . 18 years. HCV infection. G. enotype 1 or 4. Failure to a prior therapy with . SOF ± RBV + (SMV or DCV or LDV) . with documented presence of . NS5A or NS3 RASs at failure . in genotypes 1 or 3, with or without cirrhosis. >. 18 years. Chronic HCV infection. Genotype 1 or 3. HCV RNA > 10 000 IU. /ml. Treatment-naïve . Cirrhosis assessed by liver biopsy or noninvasive tests. qd. Non-randomised. Open-label. N =. 21. W12. SVR. 12. NIAID . SYNERGY GT4. Kohli. A. Lancet Infect Dis. 2015 Sep;15(9):1049-54. ≥ 18 years. Chronic HCV Genotype 4. Treatment-naïve or experienced. Open-label. Chronic HCV infection. Genotype 1 . Failure to achieve SVR. 12. . on a short-course of 1. st. line. LDV/SOF-containing regimen . No cirrhosis. N = 34. SVR. 12. Co-formulated ledipasvir-sofosbuvir (LDV 90 mg/SOF 400 mg) : 1 pill qd. SOF + SMV + RBV. SOF + SMV. Randomisation. 2 : 1 : 2 : 1*. Open-label. * . Randomisation. was stratified on genotype (1a or 1b) in both cohorts, . IL28B . in cohort 1 and treatment history (naïve or non-responder) in cohort . 400/100/100 mg QD. N = 263. N = 152. W12. Placebo. >. 18 years. Chronic HCV infection. Genotype 1, 2, 3, 4, 5 or 6. NS5A inhibitor-experienced . for ≥ 4 weeks (exclusion if . discontinued due to an adverse. Wargaming Div, MCWL, Quantico. Updated 10 Jan 2005 (see speaker notes for details). VMA. 3. HIDE. 3-16FA. A. ENY. CG47. Introduction. Comments. Table of Contents. 208. X. 100. 0. 151500Z. PHOENIX. B. ≥ 18 years. Chronic HCV infection. Genotype 1 or 4. HCV RNA > 10 000 IU/ml. Treatment-naïve or pre-treated. w. ith PEG-IFN ± RBV. Cirrhosis (> 14.5 . kPa. on . FibroScan. ). Portal hypertension or liver . April 10. –14. , 2019. Vienna, Austria. Disclaimer. These non-promotional slides are intended to be used as educational material only in response to an unsolicited question or request. The double-dagger (.